Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394453 | 0.81 | CYP3A4 (0.43) | CYP3A4CYP2C19GAATSHRALDH1A1 | |
| SCHEMBL20311441 | 0.78 | CYP3A4 (0.58) | CYP3A4CYP2C19GAATSHRALDH1A1 | |
| SCHEMBL4394013 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP2C19GAATSHRALDH1A1 | |
| SCHEMBL13485048 | 0.72 | ALOX15 (0.43) | GAAALDH1A1LMNAKMT2A | |
| SCHEMBL3736508 | 0.72 | MMP1 (0.44) | CYP3A4CYP2C19GAAALDH1A1LMNA | |
| SCHEMBL3986818 | 0.72 | SMN1; SMN2 (0.47) | CYP3A4CYP2C19GAATSHRALDH1A1 | |
| SCHEMBL8334408 | 0.71 | CYP3A4 (0.50) | CYP3A4CYP2C19GAATSHRALDH1A1 | |
| SCHEMBL6484035 | 0.70 | CYP3A4 (0.49) | CYP3A4CYP2C19GAATSHRALDH1A1 | |
| SCHEMBL15124202 | 0.70 | CYP3A4 (0.49) | CYP3A4CYP2C19GAATSHRALDH1A1 | |
| SCHEMBL10076132 | 0.70 | CYP3A4 (0.49) | CYP3A4CYP2C19GAATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090305382-A1 | ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-10 | — | — | US | disclosed |
| US-7629339-B2 | inhibitors of protein kinases and are useful in treating cancer; 4-({5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-3-methoxy-butyric acid; anticarcinogenic agent | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1926725-A1 | ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007038251-A1 | ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | PHKG1, MAP3K19, MAP3K20 | CYP3A4 4146/4885CYP2C19 3568/4885GAA 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.